(Q40093852)

17 September 2017

title

Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine (English)

1 reference

World Health Organization

17 September 2017

main subject

0 references

Dengue virus

0 references

author

Annelies Wilder-Smith

series ordinal

1

object named as

Annelies Wilder-Smith

1 reference

17 September 2017

4

Jeremy Farrar

1 reference

17 September 2017

5

Terry Nolan

1 reference

17 September 2017

3

Joachim Hombach

1 reference

17 September 2017

Kirsten S Vannice

2

1 reference

17 September 2017

language of work or name

English

0 references

publication date

5 August 2016

1 reference

Journal of Infectious Diseases

17 September 2017

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

17 September 2017

volume

214

1 reference

17 September 2017

issue

12

1 reference

17 September 2017

page(s)

1796-1799

1 reference

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Efficacy of a tetravalent dengue vaccine in children in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

The global distribution and burden of dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Critique of World Health Organization Recommendation of a Dengue Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Dengue vaccines: Are they safe for travelers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Dengue vaccines: dawning at last?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Developing evidence-based immunization recommendations and GRADE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

PUBLIC HEALTH. Dengue vaccines at a crossroad

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Beyond efficacy: The full public health impact of vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Asymptomatic humans transmit dengue virus to mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIW341

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIW341

1 reference

17 September 2017

1 reference